PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gesamtlänge aller Episoden: 10 days 18 hours 42 minutes
Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs
Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs
Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC
Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC
Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work
Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work
Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do
"Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do"
Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin
Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin
Reassessing What’s Possible in Early-Stage EGFR-mutant NSCLC: Insights from the Latest Data
Reassessing What’s Possible in Early-Stage EGFR-mutant NSCLC: Insights from the Latest Data
Best Practices in Early-Stage EGFR-Mutant NSCLC: What Surgeons Need to Know
Best Practices in Early-Stage EGFR-Mutant NSCLC: What Surgeons Need to Know
Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy
Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy
Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer
Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer